Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Prevention and risk

Topic: Brain proteins, microglia and lab models

Plain-language summary

This narrative review examines the utility of gait digital biomarkers in Parkinson's disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. The review of the literature to date suggests that upper body characteristics of gait (e.g., arm swing, trunk motion) may indicate susceptibility/risk of PD, while pace aspects (e.g., gait speed, stride length) are informative for tracking disease progression, exercise response, and fall likelihood. Dynamic stability aspects (e.g., trunk regularity, double-support time) worsen with disease progression but can improve with exercise. Gait variability emerges as a sensitive biomarker across all 4 contexts but with low specificity. The lack of standardized gait testing protocols and the lack of a minimum set of quantified digital gait biomarkers limit data harmonization across studies. Future studies, using a commonly agreed upon protocol, could be used to demonstrate the utility of specific gait biomarkers for clinical practice.

What this study adds

Evidence grade: Low

This is a narrative review. This review is about digital gait biomarkers in Parkinson's disease for tracking risk, progression, exercise response, and falls. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mancini, M., Afshari, M., Almeida, Q. J., Huffmaster, S. L. A., Balfany, K., Camicioli, R. M., et al. (2025). Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis. npj Parkinson s Disease. https://doi.org/10.1038/s41531-025-00897-1

Vancouver

Mancini M, Afshari M, Almeida QJ, Huffmaster SLA, Balfany K, Camicioli RM, et al. Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis. npj Parkinson s Disease. 2025. doi:10.1038/s41531-025-00897-1. PMID: 40118834.

BibTeX

@article{mancini2025-40118834,
  author  = {Mancini, Martina and Afshari, Mitra and Almeida, Quincy J. and Huffmaster, Sommer L. Amundsen and Balfany, Katherine and Camicioli, Richard M. and Christiansen, Cory L. and Dale, Marian L. and others},
  title   = {{Digital gait biomarkers in Parkinson’s disease: susceptibility/risk, progression, response to exercise, and prognosis}},
  journal = {npj Parkinson s Disease},
  year    = {2025},
  doi     = {10.1038/s41531-025-00897-1},
  pmid    = {40118834},
  url     = {https://doi.org/10.1038/s41531-025-00897-1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review is about digital gait biomarkers in Parkinson's disease for tracking risk, progression, exercise response, and falls. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (npj Parkinson s Disease)
Journal's citation record 1 / 4 Npj Parkinson s Disease: journal h-index 87 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 49 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 16.3 citations a year over 3 year(s) since 2025
Impact for its field and year 6 / 6 Cited 107.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 49 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Daniel M. Corcos: h-index 69 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 16 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40118834)
Free to read 2 / 2 Free to read
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Prevention and risk from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →